These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 25580985)

  • 21. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
    Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
    Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment Persistence for Infliximab Versus Adalimumab in Crohn's Disease: A 14-Year Single-Center Experience.
    Olivera P; Thiriet L; Luc A; Baumann C; Danese S; Peyrin-Biroulet L
    Inflamm Bowel Dis; 2017 Jun; 23(6):976-985. PubMed ID: 28333755
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased body mass index is associated with earlier time to loss of response to infliximab in patients with inflammatory bowel disease.
    Harper JW; Sinanan MN; Zisman TL
    Inflamm Bowel Dis; 2013 Sep; 19(10):2118-24. PubMed ID: 23863401
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk and management of intra-abdominal abscess in Crohn's disease treated with infliximab.
    Yoneno K; Hisamatsu T; Matsuoka K; Okamoto S; Takayama T; Ichikawa R; Sujino T; Miyoshi J; Takabayashi K; Mikami Y; Mizuno S; Wada Y; Yajima T; Naganuma M; Inoue N; Iwao Y; Ogata H; Hasegawa H; Kitagawa Y; Hibi T; Kanai T
    Digestion; 2014; 89(3):201-8. PubMed ID: 24803137
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study.
    Paul S; Del Tedesco E; Marotte H; Rinaudo-Gaujous M; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Roblin X
    Inflamm Bowel Dis; 2013 Nov; 19(12):2568-76. PubMed ID: 24013361
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A prospective open-label trial of Remicade in patients with severe exacerbation of Crohn's disease requiring hospitalization: a comparison with outcomes previously observed in patients receiving intravenous hydrocortisone.
    Bhatia JK; Korelitz BI; Panagopoulos G; Lobel E; Mirsky F; Sultan K; DiSanti W; Chun A; Keenan G; Mamun K
    J Clin Gastroenterol; 2007 Aug; 41(7):677-81. PubMed ID: 17667052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: a 3-year prospective randomized open trial.
    Yoshida K; Fukunaga K; Ikeuchi H; Kamikozuru K; Hida N; Ohda Y; Yokoyama Y; Iimuro M; Takeda N; Kato K; Kikuyama R; Nagase K; Hori K; Nakamura S; Miwa H; Matsumoto T
    Inflamm Bowel Dis; 2012 Sep; 18(9):1617-23. PubMed ID: 22081474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Profiles of circulating cytokines in patients with Crohn's disease under maintenance therapy with infliximab.
    Ogawa K; Matsumoto T; Esaki M; Torisu T; Iida M
    J Crohns Colitis; 2012 Jun; 6(5):529-35. PubMed ID: 22398057
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study.
    Biancone L; Orlando A; Kohn A; Colombo E; Sostegni R; Angelucci E; Rizzello F; Castiglione F; Benazzato L; Papi C; Meucci G; Riegler G; Petruzziello C; Mocciaro F; Geremia A; Calabrese E; Cottone M; Pallone F
    Gut; 2006 Feb; 55(2):228-33. PubMed ID: 16120759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease.
    Van den Brande JM; Koehler TC; Zelinkova Z; Bennink RJ; te Velde AA; ten Cate FJ; van Deventer SJ; Peppelenbosch MP; Hommes DW
    Gut; 2007 Apr; 56(4):509-17. PubMed ID: 17082252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q; Hogezand RA; Lamers CB; Verspaget HW
    Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systematic assessment of factors influencing preferences of Crohn's disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL).
    Vavricka SR; Bentele N; Scharl M; Rogler G; Zeitz J; Frei P; Straumann A; Binek J; Schoepfer AM; Fried M;
    Inflamm Bowel Dis; 2012 Aug; 18(8):1523-30. PubMed ID: 21987429
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial.
    Van Assche G; Magdelaine-Beuzelin C; D'Haens G; Baert F; Noman M; Vermeire S; Ternant D; Watier H; Paintaud G; Rutgeerts P
    Gastroenterology; 2008 Jun; 134(7):1861-8. PubMed ID: 18440315
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of infliximab on extraintestinal manifestations of Crohn's disease.
    Kaufman I; Caspi D; Yeshurun D; Dotan I; Yaron M; Elkayam O
    Rheumatol Int; 2005 Aug; 25(6):406-10. PubMed ID: 15309501
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's disease.
    Kierkus J; Dadalski M; Szymanska E; Oracz G; Wegner A; Gorczewska M; Szymanska S; Woynarowski M; Ryzko J
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):495-500. PubMed ID: 22387887
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adalimumab versus infliximab in treating post-operative recurrence of Crohn's disease: a national cohort study.
    Preda CM; Fulger LE; Negreanu L; Manuc M; Sandra I; Diculescu MM
    Rev Esp Enferm Dig; 2016 Oct; 108(10):642-647. PubMed ID: 27651132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes of OPG and RANKL concentrations in Crohn's disease after infliximab therapy.
    Miheller P; Muzes G; Rácz K; Blázovits A; Lakatos P; Herszényi L; Tulassay Z
    Inflamm Bowel Dis; 2007 Nov; 13(11):1379-84. PubMed ID: 17663430
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-TNF-alpha treatments and obstructive symptoms in Crohn's disease: a prospective study.
    Condino G; Calabrese E; Zorzi F; Onali S; Lolli E; De Biasio F; Ascolani M; Pallone F; Biancone L
    Dig Liver Dis; 2013 Mar; 45(3):258-62. PubMed ID: 23195667
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-α agents.
    Kestens C; van Oijen MG; Mulder CL; van Bodegraven AA; Dijkstra G; de Jong D; Ponsioen C; van Tuyl BA; Siersema PD; Fidder HH; Oldenburg B;
    Clin Gastroenterol Hepatol; 2013 Jul; 11(7):826-31. PubMed ID: 23376000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.